

ASX Listing Rule 4.2A

Current reporting period:
Previous reporting period:

Half Year ended 31 December 2021
Half Year ended 31 December 2020

Results for announcement to the market		Percentage change %	31 Dec 2021 \$'m
<i>Statutory</i>			
Total revenue from ordinary activities	Up	69.2%	538.0m
Profit attributable to member of Australian Clinical Laboratories Limited	Up	128.1%	130.2m
<i>Pro forma</i>			
Total revenue from ordinary activities	Up	62.1%	538.0m
Profit attributable to member of Australian Clinical Laboratories Limited	Up	200.7%	130.2m

In line with the prospectus dated 28 April 2021 pro forma financials reported above adjust are on a normalised basis to remove for initial public offer (IPO) transaction costs, SunDoctors acquisition and other significant one off costs. These are discussed in full in the 2021 Annual Financial Report.

Earnings per Share		Percentage change %	31 Dec 2021 Cents per share
<i>Statutory</i>			
Basic and diluted earnings per Share	Up	64.4%	64.54c
<i>Pro forma</i>			
Basic and diluted earnings per Share	Up	116.6%	64.54c

Dividends	Amount per security Cents per share	Franked amount per security Cents per share
FY2022		
Interim dividend	12.00c	12.00c
FY2021		
Interim dividend	Nil	Nil
Record date for determining entitlements to the interim dividend	28 March 2022	

There is a dividend reinvestment plan in operation. The last day for the receipt of an election notice for participation is Tuesday 29 March 2022.

Commentary on results for the period

For an explanation of the results refer to the ASX and media release and Half Year Report.

This report is based on the Half Year Financial Report which has been reviewed by Pitcher Partners. Additional Appendix 4D disclosure requirements can be found in the Half Year Financial Report attached, which contains the Directors' Report, the Directors' Declaration and the consolidated financial statements for the half year ended 31 December 2021.

This information should be read in conjunction with the 2021 Annual Report and public announcements made in the period by Australian Clinical Labs Limited, in accordance with the continuous disclosure requirements of the Corporations Act 2001 and ASX Listing Rules.